scholarly journals Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations

2011 ◽  
Vol 41 (8) ◽  
pp. 959-963 ◽  
Author(s):  
S. Matsuura ◽  
N. Inui ◽  
Y. Ozawa ◽  
Y. Nakamura ◽  
M. Toyoshima ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document